Lumoptik Inc.
Providing prolonged drug delivery inside the eye
This article was originally published in Start Up
Executive Summary
VEGF inhibitors have revolutionized the treatment of age-related macular degeneration, but there’s no getting around the need for lifelong, monthly injections straight into the eye. Lumoptik Inc. has developed a precision navigation system that may allow for more effective, prolonged drug delivery, resulting in less frequent injections over the same time period.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.